Weekly · monthly · quarterly news summaries, side by side in time
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.
First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.
First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.